Histogenics reported second quarter financial results as the company moves forward with the NeoCart Phase III Trial.
Here are five key notes:
1. The second quarter net loss attributable to common stockholders was $7.6 million, or $0.58 per share. This is lower than $11.8 million and $19.85 per share last year.
2. Research and development expenses hit $5.9 million in the second quarter, up from $4.7 million over the same period last year. There was increased activity and enrollment in the NeoCart Phase III clinical trial.
3. The company reported $45.2 million in cash, cash equivalents and marketable securities. The company believes its current cash position will fund operations into 2017.
4. There were new investigators joining the NeoCart trial last quarter, including Kaiser Permanente patients in California.
5. The company hired Jon Lieber and Gloria Mathews in the C-suite.